Literature DB >> 7942182

Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation.

J Yoshida1, Y Kajita, T Wakabayashi, K Sugita.   

Abstract

We analysed long-term follow-up results of 175 patients with malignant glioma (110 glioblastoma and 65 anaplastic astrocytoma) treated under five different regimes during the past two decades. The factors of age (less than 40), histology (anaplastic astrocytoma) and type of adjuvant therapy (radiation and chemotherapy) contributed to long survival. The other important factor was the response to adjuvant therapy. Cases of gross total removal or complete response (CR) of a residual tumour to an adjuvant therapy showed a better prognosis. The three and five year survival rate was 42% and 24%, respectively. The highest CR ratio (23%) was seen in patients treated by intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942182     DOI: 10.1007/bf01808547

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  17 in total

1.  Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.

Authors:  M Ammirati; N Vick; Y L Liao; I Ciric; M Mikhael
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

2.  Mechanism of the antitumour effect of interferon in mice.

Authors:  I Gresser; C Maury; D Brouty-Boyé
Journal:  Nature       Date:  1972-09-15       Impact factor: 49.962

3.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme.

Authors:  P C Burger; S B Green
Journal:  Cancer       Date:  1987-05-01       Impact factor: 6.860

4.  Clinical effect of interferon in malignant brain tumours.

Authors:  M Nagai; T Arai
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

5.  Long-time survival of a patient with glioblastoma and Turcot's syndrome. Case report.

Authors:  H P Rutz; N de Tribolet; J M Calmes; G Chapuis
Journal:  J Neurosurg       Date:  1991-05       Impact factor: 5.115

6.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

Authors:  W R Shapiro; S B Green; P C Burger; M S Mahaley; R G Selker; J C VanGilder; J T Robertson; J Ransohoff; J Mealey; T A Strike
Journal:  J Neurosurg       Date:  1989-07       Impact factor: 5.115

Review 7.  Magnetic resonance imaging of the brain and spine. Is clinical efficacy established after the first decade?

Authors:  D L Kent; E B Larson
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Cytotoxicity of human beta-interferon produced in human glioma cells transfected with its gene by means of liposomes.

Authors:  J Yoshida; M Mizuno; K Yagi
Journal:  Biochem Int       Date:  1992-12

10.  Effects of ACNU and radiotherapy on malignant glioma.

Authors:  K Takakura; H Abe; R Tanaka; K Kitamura; T Miwa; K Takeuchi; S Yamamoto; N Kageyama; H Handa; H Mogami
Journal:  J Neurosurg       Date:  1986-01       Impact factor: 5.115

View more
  26 in total

1.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Quantitation of O6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas.

Authors:  Satoshi Tanaka; Hidehiro Oka; Kiyotaka Fujii; Kaoru Watanabe; Kumi Nagao; Atsushi Kakimoto
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

3.  Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.

Authors:  Atsuo Yoshino; Yoichi Katayama; Takakazu Yokoyama; Takao Watanabe; Akiyoshi Ogino; Takashi Ota; Chiaki Komine; Takao Fukushima; Kaoru Kusama
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.

Authors:  Takaaki Beppu; Katsura Kamada; Ryuji Nakamura; Hiroshi Oikawa; Masaru Takeda; Takeshi Fukuda; Hiroshi Arai; Kuniaki Ogasawara; Akira Ogawa
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

5.  Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.

Authors:  Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 6.  Cytokine networks in glioma.

Authors:  Kenichiro Iwami; Atsushi Natsume; Toshihiko Wakabayashi
Journal:  Neurosurg Rev       Date:  2011-06-09       Impact factor: 3.042

7.  Therapy of glioblastoma multiforme: a cumulative experience of 10 years.

Authors:  A Obwegeser; M Ortler; M Seiwald; H Ulmer; H Kostron
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

8.  Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.

Authors:  Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Chikashi Fukaya; Takamitsu Yamamoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

9.  Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma.

Authors:  T Wakabayashi; N Hatano; Y Kajita; T Yoshida; M Mizuno; K Taniguchi; T Ohno; T Nagasaka; J Yoshida
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

10.  Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Authors:  M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.